enekinragene inzadenovec
Phase 2- Indications
- Osteoarthritis of the knee
Company intelligence / Profile preview
GQ Bio’s lead gene therapy candidate, PCRX‑201, demonstrated sustained improvements in knee pain, stiffness, and function through two years after local administration in a large Phase 1 study for osteoarthritis of the knee. The product was well tolerated with no major adverse events. A randomized double-blind Phase 2 trial is being initiated by Pacira. Other pipeline assets remain preclinical
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GQ Bio Therapeutics.